Product Dossier
TALAM
Product Dossier for TALAM (citalopram (as hydrobromide), Arrotex Pharmaceuticals). ARTG record, PBS listing, PBAC outcomes — compiled by arcimedes.
- Sponsor: Arrotex Pharmaceuticals
- Active ingredient: citalopram (as hydrobromide)
- Therapeutic area: Psychiatry
- Same area: REXULTI
- Same area: NICORETTE
What it is
TALAM is a citalopram hydrobromide tablet formulation registered on the Australian Register of Therapeutic Goods (ARTG). The product is available in strengths of 10 mg, 20 mg and 40 mg.
Approved indications
The provided source documents do not contain information about the approved indications for TALAM.
Dosing overview
The provided source documents do not contain information about dosing recommendations for TALAM.
Key safety warnings
The provided source documents do not contain information about key safety warnings for TALAM.
Contraindications
The provided source documents do not contain information about contraindications for TALAM.
PBS listing
The provided source documents do not contain information about PBS listing details for TALAM.
Regulatory history
TALAM citalopram 20 mg was first registered on the ARTG on 7 March 2003 as a tablet in blister pack format. Additional formulations were registered on 9 September 2013, including TALAM citalopram 20 mg tablets in both bottle and blister pack formats under licence category RE. TALAM citalopram 10 mg and 40 mg tablet formulations in blister packs were registered on 7 May 2015 under licence category RE.